DAB2IP and cancer: Mechanistically, DAB2IP interacts with RAC1 and impedes RAC1-mediated β-catenin nuclear translocation, so that DAB2IP loss promotes the induction of cancer stem cell phenotypes and DOC resistance [35, 36].